Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encoberminogene rezmadenovec - Cornell University/Xylocor Therapeutics

Next Previous
Drug Profile

Encoberminogene rezmadenovec - Cornell University/Xylocor Therapeutics

Alternative Names: AdVEGF-A116A+ gene therapy - XyloCor Therapeutics; AdVEGF-All6A+; AdVEGFXC1; XC-001

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University
  • Developer Cornell University; XyloCor Therapeutics
  • Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Angina pectoris; Coronary artery disease

Most Recent Events

  • 12 Aug 2025 XyloCor Therapeutics plans a phase II EXACT-CABG trial for Coronary artery disease in USA (Intracardiac) in August 2025 (NCT07118449)
  • 24 Jun 2025 Phase-II clinical trials in Coronary artery disease (Treatment-resistant) in USA (Intracardiac) (NCT07048808)
  • 24 Jun 2025 XyloCor Therapeutics initiates enrolment in a phase II EXACT-2 trial for Angina pectoris (Treatment-resistant) in USA (NCT07048808)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top